POGO

icon-facebook

POGO Satellite Manual

3.3 Extravasation Management

3.3.1 Prevention and Management of Extravasations

Download Word version
Download PDF version

Guidance for Prevention of Extravasation

Vesicant antineoplastic agents should be administered by qualified personnel. Vesicant/irritant drugs should be administered via Central Venous Catheters (CVCs) whenever possible. It is highly recommended that all infusions of vesicants be given via a CVC.

Consider the following measures to prevent extravasation:

  1. Anticipate the possibility of extravasation.
  2. Ensure extravasation treatment protocol and antidotes are readily available.
  3. Careful vein selection for PIVs. (See section below.)
  4. Minimize number of venipunctures in starting PIVs.
  5. Ensure good blood return from site prior to and during administration and upon completion.
  6. Ensure free flowing intravenous fluids during administration of vesicant chemotherapy when applicable.
  7. Frequent monitoring of PIV/port needle sites or CVC site and monitor for increase in pump pressures.

Extravasation supplies should be available.

Starting a New PIV for Administration of Vesicant Drugs

Choose PIV site carefully. Choose the most distal position of a vein and in this order if possible:

  1. Dorsum of hand
  2. Forearm
  3. Wrist (potential damage to tendons and nerves should extravasation occur)

Avoid the antecubital fossa since this area is dense with tendons and nerves; damage here can result in loss of structure and function.

If first attempt is unsuccessful, select another site preferably in another limb. Avoid a distal point in the same vein because of the potential for extravasation “downstream.”

Guidance for Management of Extravasation of Vesicant

The following guidance is recommended for the management of extravasation. The medical team should be notified immediately and treatment must be individualized to each extravasation event. 

For an immediate intervention, follow the SLAPP mnemonic:

  • S = Stop the infusion and assess the area
  • L = Leave the needle or catheter in place
  • A = Aspirate
  • P = Pull the needle
  • P = Provider should be notified
Important StepsKey Points
STOP the IV infusion.
Do not remove the IV/port needle yet.
Click here to access the Flowchart available for quick reference.
Detach IV tubing/syringe from the IV/port needle. Attach a new syringe to the IV/port needle as close as possible to insertion site. Aspirate as much drug, blood and tissue fluid as possible. Remove the syringe. 
Notify the medical team of extravasation as soon as possible. 
REMOVE the original angiocatheter/port needle. 
Consult Sub-Section 3.3.2 Antidotes and Treatment for Extravasation. Notify Pharmacy. 
Continue as per table below for each drug. 
Administer analgesics as ordered.Corticosteroid cream (e.g., hydrocortisone 1% cream) may reduce inflammation. Silver Sulfadiazine cream, povidone iodine ointment or sterile dressings may also provide symptomatic relief or prevent secondary infection.
For PIVs, restart the IV at another site, preferably in the opposite limb or in the same limb proximal to the infiltrated area, if needed.
For Port-a-catheter, re-access to heparin lock.
 
Immobilize the affected limb or area. Elevate the affected area to promote venous drainage and to reduce edema.
Document the extravasation occurrence in the patient’s chart and complete your hospital Safety Report. Delineate the infiltrated area on patient’s skin with a permanent marker. Photo documentation may be helpful. Consent may be required. 
Consult Plastics upon Medical Doctor (MD)/Nurse Practitioner (NP) discretion and/or no improvement of site in 24 hours. 
Extravasation known: Follow up as directed by Plastics. If Plastics not consulted, return to clinic in 24–48 hours for assessment, then weekly for one month minimum.
Extravasation suspected: Telephone call in 24 hours by nurse to assess and then in one week minimum.
Provide information to patient/family with what to look for and when to call. The site should be observed daily by the patient and/or parent for one month as there may be delayed reaction.

Guidance for Management of Extravasation of Irritant Drugs

The following guidance is recommended for the management of extravasation of irritant drugs. The medical team should be notified immediately and treatment must be individualized to each patient. While the medical team may elect to use an antidote if one exists, or topical medications, it is important to realize that many patients recover fully with no drug treatment at all.

Important StepsKey Points
Stop IV infusion.
Do not remove angiocatheter/port needle yet.
Click here to access the Flowchart available for quick reference.
Detach IV tubing/syringe from IV/port needle. Attach a new syringe to IV/port needle as close as possible to insertion site. Aspirate as much drug, blood, and tissue fluid as possible. Remove the syringe. 
Notify the medical team of extravasation as soon as possible. 
REMOVE the original angiocatheter/port needle. Dispose in proper hazardous waste container. 
Continue as per Sub-Section 3.3.2 Antidotes and Treatment for Extravasation for each drug. 
Administer analgesics as ordered.Corticosteroid cream (e.g., hydrocortisone 1% cream) may reduce inflammation. Silver Sulfadiazine cream, Povidone iodine ointment or sterile dressings may also provide symptomatic relief or prevent secondary infection.
For PIVs, restart the IV at another site, preferably in the opposite limb or in the same limb proximal to the infiltrated area, if needed.
For Ports, re-access to heparin lock or re-establish IV.
 
Immobilize the affected limb or area. Elevate the affected area to promote venous drainage and to reduce edema. 
Document the extravasation of occurrence in the patient’s chart and complete your hospital safety report. Delineate the infiltrated area on the patient’s skin with a permanent marker. Photo documentation may be helpful. Consent may be required. 
Consult Plastics upon MD or Nurse Practitioner discretion and/or no improvement of site in 24 hours. 
Extravasation known: Follow up as directed by Plastics. If Plastics not consulted, return to clinic in 24–48 hours for assessment, then weekly for one month minimum.
Extravasation suspected: Telephone call in 24 hours by nurse to assess and then in one week minimum.
Provide information to patient/family with what to look for and when to call. The site should be observed daily by the patient and/or parent for one month as there may be delayed reaction. Click here for sample documents.

This guidance document was developed by Ms. Julie Dowler, Ms. Denise Reniers and Ms. Anne Chambers, Children’s Hospital, London Health Sciences Centre, London, in consultation with Ms. Lisa Honeyford, The Hospital for Sick Children, Ms. Kirsty Morelli, Scarborough Health Network and Ms. Mary Jo Decourcy, London Health Sciences Centre, based on the sources in Sub-Section 3.3.4.

Disclaimer: Source Accuracy

You are welcome to download and save a local copy of this document in the Word and/or PDF formats provided. As the POGO Satellite Manual is subject to ongoing revisions and updates by POGO, we recommend you regularly check the online version posted at https://www.pogo.ca/satellite-manual/ to ensure you have the most up-to-date content. In the event of any inconsistency between the content of a local copy and the online version of the POGO Satellite Manual, the content of the online version shall be considered correct. Please see also the POGO Satellite Manual Disclaimer.

Record of Updates
Version NumberDate of EffectSummary of Revisions
16/28/2021Original version posted.
3.3.2 Antidotes and Treatments for Extravasation
Back to Top

In this Section

  • 1.1 History and Overview
  • 1.2 Acknowledgements
  • 1.3 Committees and Working Groups
  • 1.4 POGO Satellite Manual Disclaimer
  • 2.1 Principles of POGO Satellite Clinic Care
  • 2.2 Eligible Patients
    • 2.2.1 Children Eligible for Chemotherapy Administration in a POGO Satellite Clinic
    • 2.2.2 Children Eligible for the Management of Complications in a POGO Satellite Clinic
    • 2.2.3 Children Eligible for Supportive Care in a POGO Satellite Clinic
  • 2.3 Scope of POGO Satellite Clinic Practice
  • 2.4 Expanded POGO Satellite Clinic Practice
  • 3.1 Safe Handling, Administration and Disposal of Chemotherapy Agents
    • 3.1.1 Personal Protective Equipment
    • 3.1.2 Preparation, Transport and Storage
    • 3.1.3 Administration of IV Hazardous Drugs
    • 3.1.4 Administration of Oral Hazardous Drugs
    • 3.1.5 Disposal of Equipment/Personal Protective Equipment used to Administer Hazardous Drugs
    • 3.1.6 Safe Handling for Pharmacy
    • 3.1.7 References
  • 3.2 Accidental Exposure/Spills
  • 3.3 Extravasation Management
    • 3.3.1 Prevention and Management of Extravasations
    • 3.3.2 Antidotes and Treatments for Extravasation
    • 3.3.3 Sample Extravasation Documenting Tool
    • 3.3.4 References
  • 3.4 Injecting SC Medication Via an Insuflon
  • 3.5 Chemotherapy Administration Reference List
  • 3.6 Central Venous Catheter Care
  • 3.7 Chemotherapy Quick Reference
    • 3.7.1 Rapid Hydration
    • 3.7.2 Provider Guide: Prevention and Management of Irinotecan-Induced Diarrhea
    • 3.7.3 Capizzi Methotrexate
    • 3.7.4 Erwinia Asparaginase
  • 4.1 Management of Fever and Neutropenia
    • 4.1.1 Routine Order Sample Sheet
    • 4.1.2 Sample Fever Cards
    • 4.1.3 Criteria for low-risk designation. Risk categorization refers to risk of bacteremia and serious complications, including mortality.
  • 4.2 Pentamidine Administration
    • 4.2.1 Inhaled Pentamidine
    • 4.2.2 Intravenous Pentamidine
  • 4.3 Antiemetics
  • 4.4 Treatment of Varicella-Zoster Infections
  • 4.5 Immunization of Children with Cancer
  • 4.6 Transfusion
  • 4.7 Clinical Circumstances that Warrant Consultation with the Specialized Childhood Cancer Program
  • 5.1 Palliative Care Overview
  • 5.2 Communication
  • 5.3 Settings of Care
  • 5.4 Symptom Management
  • 5.5 End of Life
  • 5.6 When a Child Dies at the POGO Satellite Clinic
  • 5.7 Appendix: Sample Bereavement Materials
    • 5.7.1 Reconciling Your Grief
    • 5.7.2 Funeral Arrangement Checklist
    • 5.7.3 Helping Children Who Grieve
    • 5.7.4 Coping with the Holidays
    • 5.7.5 The Grief Experience
  • 5.8 References
  • 6.1 Goals and Objectives
  • 6.2 Participant Site Selection
    • 6.2.1 Tertiary Hospital Site Selection
    • 6.2.2 Community Hospital Site Selection
  • 6.3 POGO’s Roles
    • 6.3.1 PHIPA, Privacy and Research
  • 6.4 Funding
    • 6.4.1 Funding Support for Tertiary Hospital Activity
    • 6.4.2 Funding Support for Community Hospital Activity
  • 6.5 Infrastructure and Formal Requirements
    • 6.5.1 Specialized Childhood Cancer Program Partners’ Role in the POGO Satellite Program
    • 6.5.2 POGO Satellite Clinic Partners’ Role in the POGO Satellite Program
  • 7.1 Preamble
  • 7.2 Investigator Responsibilities
  • 7.3 Training Requirements
    • 7.3.1 General Training for Conduct of Research
    • 7.3.2 Protocol-Specific Training
  • 7.4 Research Activities That May Be Completed in POGO Satellite Clinics Under Supervision of DSI
  • 7.5 Research Activities to be Completed in Specialized Childhood Cancer Programs Only
  • 7.6 Recognition and Reporting of Adverse Events (AEs)
  • 7.7 Data Transfer
  • 7.8 Pharmacy Drug Accountability
  • 7.9 Site Inspections and Quality Assurance
  • 8.1 Pediatric Oncology Shared Care Initial Data Transfer Sheet
  • 9.1 POGO Satellite Clinic Preparedness Checklist
  • 9.2 POGO Satellite Clinic Quality Assurance Checklist
Back to table of contents
Search our Manual
Have a question?
Contact us at: satellite@pogo.ca
  • About Us
    • Our Mission and Vision
    • Childhood Cancer Care Plan
    • POGO Land Acknowledgement
    • Diversity, Equity, Inclusion
    • Our Board
    • Our Partners
    • Our Donors
    • Privacy
    • Accessibility
    • Reports
    • Newsroom
    • Job Opportunities
    • Staff List
  • Programs & Support
    • Patient Care Programs
    • Financial Assistance
    • Survivor Care
    • Cancer Resources
    • Inspiring Stories
    • Clinical and Program Advisory Committees
  • Education
    • POGO Satellite Education Day
    • POGO Virtual Education
    • Indigenous Resource Guide
    • All Education Events & Conferences
  • Healthcare Practice
    • COVID-19 Updates
    • Pediatric Oncology Nursing
    • Clinical Practice Guidelines
    • POGO Satellite Manual
  • Research & Data
    • 2020 POGO Surveillance Report
    • POGO Research Unit
    • POGONIS – Childhood Cancer Database
    • Data Reports
    • Data Requests
  • Get Involved
    • Pajamas and Pancakes
    • Birthday Parties for POGO
    • Events
    • Volunteer
  • Ways to Give
    • Donate
    • Monthly Donations
    • Gifts of Stock and Securities
    • Become a Corporate Partner
    • Gifts in Honour/Memory
    • Legacy Gifts
    • Shop Online/Earn Cash Back

©2022 Pediatric Oncology Group of Ontario

480 University Avenue, Suite 1014 | Toronto, Ontario, M5G 1V2, Canada | Charitable Registration Number: 871067245RR0001 |
1-855-FOR POGO (367-7646) | Contact Us | Website Privacy Policy | Website Disclaimer | Satellite Manual Disclaimer |